Consider Ingrezza When Treatment Is Needed for Tardive Dyskinesia
June 2017
The approval of Ingrezza (in-GREH-zah, valbenazine) will raise questions about how to treat tardive dyskinesia.
Up to 30% of patients on long-term antipsychotics develop tardive dyskinesia. It's usually associated with higher doses, longer duration, and higher-potency typical antipsychotics, such as haloperidol.
But it can also occur with atypical antipsychotics, such as risperidone...and other dopamine blockers, such as metoclopramide.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote